Taletrectinib is already approved in the U.S., China and Japan for advanced ROS1-positive non-small cell lung cancer TOKYO and NEW YORK, NY., Mar 27, 2026 - (JCN Newswire) - Eisai Co., Ltd.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results